Protein / target
Farnesyl pyrophosphate synthase
Protein at a glance
Biological role
(2E,6E)-farnesyl diphosphate synthase activity
Strongest disease association
porokeratosis 9, multiple types
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
11 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate
Subcellular location
Domains and Gene Ontology detail (16)Hide
Gene Ontology
- Ccytoplasm
- Ccytosol
- Cmitochondrial matrix
- Cperoxisome
- F(2E,6E)-farnesyl diphosphate synthase activity
- Fdimethylallyltranstransferase activity
- Fmetal ion binding
- FRNA binding
- Pcholesterol biosynthetic process
- Pcholesterol biosynthetic process via desmosterol
- Pcholesterol biosynthetic process via lathosterol
- Pfarnesyl diphosphate biosynthetic process
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Metabolic enzyme activity
- ·dimethylallyltranstransferase activity
Transcriptional regulation
- ·Activation of gene expression by SREBF (SREBP)
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Farnesyl diphosphate synthase inhibitor
Appears in clinical studies involving metastasis, plasma cell myeloma, prostate carcinoma, bone Paget disease
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 276 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 11 total
breast cancer · plasma cell myeloma · Bone pain
Paget disease · bone disorder · bone Paget disease
postmenopausal osteoporosis · osteoporosis · Paget disease
Hypercalcemia · bone disorder · osteogenesis imperfecta
postmenopausal osteoporosis · osteoporosis · injury
Hypercalcemia · lung cancer · breast cancer
metastasis · plasma cell myeloma · prostate carcinoma
osteoporosis · bone Paget disease · postmenopausal osteoporosis
osteoporosis · Paget disease · postmenopausal osteoporosis
osteoporosis · metastasis · bone fracture
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Withdrawn from market
Market withdrawal: Zoledronic acid medac (EMA)
- Withdrawn from market
Market withdrawal: Zoledronic acid Actavis (EMA)
- Withdrawn from market
Market withdrawal: Zoledronic Acid Hospira (EMA)
- New publicationTreatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
- New publicationA Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
- New publicationBone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
- Regulatory approval
Approval: Zoledronic Acid Accord (EMA)
- New publicationRe-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study.
- Regulatory approval
Approval: Zoledronic acid Mylan (EMA)
- Regulatory approval
Approval: Zoledronic acid Teva (EMA)
- New publicationRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
- New publicationZoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.